On December 5, 2016, United Laboratories International Holdings Ltd. (“United Laboratories”, 03933.HK) successfully issued US$ 180 million convertible bonds with a coupon of 4.5% due in five years.

United Laboratories adopts the vertically integrated business model which combines R&D, production and operation. It owns many production sites in the country and can provide a variety of pharmaceutical products, especially of antibiotics and its bulk medicine and intermediate. United Laboratories is among the first batch of domestic drug companies which pass the national GMP certification for all its formulations all at once. Its domestic subsidiary has won titles such as “Guangdong New and High Technology Company”, “China’s Top 100 Drug Maker”, ” Guangdong Advanced Organization”, etc.

Jingtian & Gongcheng is the PRC legal counsel for the issuer to provide comprehensive legal services.